Biogen used unlawful, anticompetitive agreements with key pharmacy benefit managers to block the distribution of US generic versions of its Tecfidera (dimethyl fumarate) while it “scrambled” to switch the market to its follow-on brand Vumerity (diroximel fumarate) for multiple sclerosis, according to a class action lawsuit.
Filed by health-benefit plan Local No. 1 Health Fund in the US District Court for the Northern District of Illinois, the suit accuses Biogen and its PBM “co-conspirators” of an unlawful scheme to impair generic competition, which maintained monopoly and supracompetitive prices and prevented Local No